Nastech Pharmaceutical’s top official last week said that the company is considering dropping plans to spin out its RNAi therapeutics assets into a new publicly traded firm amid financial troubles including a sharp drop in share price, in part tied to the termination of a non-RNAi drug-development collaboration.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.